Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Agilon Health, Inc....
-
AVITA Medical to Host Investor Webinar Briefing
-
AVITA Medical reported financial results for the third quarter ended September 30, 2025
-
AVITA Medical data at SRBC 2025 confirms RECELL® as standard of care, improving healing, reducing hospital stays, and lowering treatment costs
-
AVITA Medical to announce Q3 2025 financial results on Nov 6; webcast to discuss performance and business highlights
-
MSAC backs AVITA Medical’s RECELL® for burns, recognizing its safety, healing benefits, donor site sparing, and reduced hospital stays.
-
Avita allegedly revealed unpaid claim backlogs for Recell procedures, causing provider uncertainty and a 21% stock drop on August 8, 2025.
-
Avita revealed a six-month backlog of unpaid Recell claims due to CMS pricing delays, hurting demand and driving shares down 21% to $4.25 on August 8, 2025
-
Avita revealed CMS pricing delays caused a 6-month backlog in unpaid Recell claims, hurting demand; shares fell 21% to $4.25 on Aug 8, 2025.
-
Avita revealed a six-month backlog of unpaid Recell claims, hurting demand. Shares fell $1.13, or 21%, from $5.38 on Aug 7 to $4.25 on Aug 8, 2025.